# Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection

> **NCT02241187** · NA · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 2 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** PEGPH20
- **DRUG:** Cetuximab
- **DEVICE:** DW & DCE-MRI
- **OTHER:** blood draws

## Key facts

- **NCT ID:** NCT02241187
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-12
- **Primary completion:** 2016-09-13
- **Final completion:** 2016-09-13
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2017-09-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02241187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02241187, "Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02241187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*